Compare GTLB & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLB | GRFS |
|---|---|---|
| Founded | 2011 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.2B |
| IPO Year | 2021 | 2006 |
| Metric | GTLB | GRFS |
|---|---|---|
| Price | $34.28 | $8.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 27 | 2 |
| Target Price | ★ $51.62 | $10.15 |
| AVG Volume (30 Days) | ★ 4.1M | 485.7K |
| Earning Date | 03-02-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.60% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | $906,253,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $27.21 | $5.36 |
| Revenue Next Year | $19.06 | $5.15 |
| P/E Ratio | ★ N/A | $17.46 |
| Revenue Growth | ★ 27.36 | 7.31 |
| 52 Week Low | $33.92 | $6.19 |
| 52 Week High | $74.18 | $11.14 |
| Indicator | GTLB | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 31.46 | 44.66 |
| Support Level | $34.04 | $8.79 |
| Resistance Level | $36.73 | $9.40 |
| Average True Range (ATR) | 1.30 | 0.24 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 6.34 | 12.18 |
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.